Lisata Therapeutics Inc LSTA

$1.06 +0.06 (6.44%)

Valuation

Market cap
10,760,000
Revenue TTM
$170,000
Net income TTM
$-16,590,000
PE ratio
0.00
Forward PE
—
Profit margin
-9,758.82%
Debt to equity
0.00

Trading

Volume
60,300
Avg volume
349,548
Day's range
$0.96 – $1.06
Shares out
10,804,000
Stochastic %K
83%
Beta
0.94
Analysts
Hold
Price target
$4.00

Price

Company profile

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cance...

Show more

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. Lisata Therapeutics, Inc. was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. in September 2022. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Industry
Biotechnology
Sector
Healthcare
Phone
908 842 0100
Website
https://www.lisata.com
Address
110 Allen Road, 2nd Floor, Basking Ridge, United States

Latest news

Stocktwits

bulmar Oct 26, 2:33 PM
$LSTA Ince I saw retail claiming to own a large portion of this stock near 2 bucks I was like run away..
0 replies
ikkydiphoenix Oct 15, 11:53 AM
$LSTA kuva's original offer was over 6 simes higher than now. I find it hard to believe that the new offer they made was lower than 1$ so it looks like CEO is once again actain against shareholders best interests. I think Marea shareholders should be worried to merge business with Mr. Mazzo.
0 replies
Defen Oct 14, 2:18 PM
$LSTA reverse coming Dilution Sounds very familiar to other small bios bag holders
0 replies
longshot45 Oct 12, 5:29 PM
$LSTA 52 week low appears to be holding… for now. The precipitous drop however gives me the feeling we’re going to see the floor break sometime this week
0 replies
Biotech_Pharma_Investor Oct 12, 3:12 PM
$LSTA Could it be that this going down due to the planned RS for the merger?? (silly if yes)
2 replies
Biotech_Pharma_Investor Oct 12, 2:55 PM
$LSTA Is this getting cheap again?? Not as simple a set-up as before. But the merged company will be a very decent company with great assets and runway through 2028. Funding at $1.49 ($225M). @skyrockets_Inc
1 replies
SQUEAKSBANDIT Oct 10, 4:08 AM
$LSTA what a frikkin bust hope you sucker buyers didn't pay 1.50 for these toxic shares 2.5% of the new company !!! ahhhhhhhhh
1 replies
ikkydiphoenix Oct 9, 5:52 PM
$LSTA what a scam, i wont be surprised if they agreed with kuva all this sh1tshow..
0 replies